Topical Analgesics Market is segmented By Drug Type(Non-Opioids, Nonsteroidal anti-inflammatory drugs (NSAIDS), Capsaicin, Lidocaine, Methyl salicylates, Other), By Formulation(Cream, Patch, Spray, Gel, Others), By Distribution Channel(Pharmacies & Drug stores, E-commerce, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Topical Analgesics Market Overview
Topical Analgesics Market is estimated to grow high at a CAGR of 4.31% during the forecast period (2022-2029).
Topical analgesic medication is applied to body surfaces such as the skin or mucous membranes to treat painful ailments; it is either rubbed onto the skin or made into patches or plasters applied to the skin.
Topical Analgesics Market Scope
| Metrics | Details |
| Market CAGR | 4.31% |
| Segments Covered | By Drug Type, By Formulation, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Download Sample
Topical Analgesics Market Dynamics
The factors expected to drive the market growth are the rise in the adoption of topical analgesics and the increasing prevalence of problems associated with pain.
The rise in the adoption of topical analgesics is expected to boost the market growth in the forecast period.
In proportion to the advancement of knowledge of pain mechanisms, there has been an increasing emphasis on developing new routes of drug administration to provide tailored treatments for patients without decreasing analgesia efficacy. While acute pain serves as a warning sign, chronic pain is a syndrome that necessitates the careful selection of analgesic drugs with high bioavailability for long-term use. Such criteria are obstacles that topical medications seek to overcome, allowing for progressive delivery of active components while maintaining stable plasma levels and a good safety profile. As the understanding of pain pathophysiology and treatment is growing, new drug delivery routes are being discovered to block pain at peripheral sites with the most active drug and the most negligible systemic effects. Topical preparations are the result of such research.
For instance, the easiest route for patients is to apply analgesics directly to the site of soreness, even if the sensation is referred pain from another source. They believe that oral treatments have a higher risk of side effects than topical treatments. Furthermore, administering localized therapy to the lay population may increase the efficacy of the placebo component of topical analgesia. Topical analgesics or anesthetics are liquids, gels, powders, creams, semisolids, emulsions, patches, foams, or aerosols that contain an analgesic or anesthetic agent and are applied to or near the painful site. Most topical preparations are available in patches, ointments, or creams. Hence, the ease of using topical analgesics for pain relief is expected to fuel the market growth.
The side effects of topical analgesics are expected to hamper the global topical analgesics market.
Most topical analgesics may have side effects such as skin stinging/burning/tingling sensation, hypersensitivity reaction. Capsaicin side effects may include a temporary increase in pain at the application site, erythema at the application site (redness), the sensation of burning at the application site, hurt in a limb, nausea, vomiting, high blood pressure, skin dries out, swelling, itching, an abscess (bumps in the skin), blisters, edema, chronic sinusitis (inflammation of sinus), bronchitis (rash of bronchial passage), nasopharyngitis (inflammation of nasal passage and pharynx), infection of the upper respiratory tract. They can cause irritated skin and have a strong odor or unpleasant odor.
For instance, topical lidocaine is generally considered safe. Misuse, overuse, or overdose, on the other hand, can result in a variety of severe health issues, including death. Ingesting lidocaine can cause numbness in the mouth and throat, causing difficulty swallowing and even choking.
COVID-19 Impact Analysis
COVID-19 implemented a national wide lockdown, government regulations, and increased infection rates across the country all had a significant financial impact on clinics and pain services. Many clinics and pain services have decreased patient visits because of COVID-19, ultimately reducing client contact. Furthermore, most chronic pain facilities were designated as non-urgent, and both outpatient and elective interventional procedures were restricted or discontinued during the COVID-19 pandemic to reduce the risk of viral spread. The COVID-19 outbreak is expected to impact the global topical analgesic market's growth. For instance, patients with COVID-19 who are receiving opioid treatment may be more susceptible to respiratory depression, and fentanyl drug absorption during transdermal administration, such as fentanyl patch, may increase with fever potentially increasing opioid side effects. Patients who are prescribed transdermal opioids drugs, on the other hand, experience side effects such as sedation, nausea and vomiting, and respiratory depression. As a result, COVID-19 is expected to have affected the global topical analgesics market.
Topical Analgesics Market Segment Analysis
The non-opioids segment is expected to dominate the market growth based on drug type.
Non-opioid analgesics are over-the-counter (OTC) and prescription pain relievers. In various clinical settings, they are increasingly being emphasized as a preferred, safe, and effective first-line therapy alternative to opioid medications for mild to moderate acute and chronic pain. For instance, non-opioid topical medications, such as lidocaine and capsaicin, are applied to the skin and thus have a local effect. Lidocaine works by inhibiting nerve signals that transmit pain sensations from the injury site to the brain. It causes a temporary loss of success in the area where it is used. Capsaicin appears to deplete local neurons of substance, which is required for nociceptive input transmission. NSAIDs have a high concentration in the dermis, synovium, muscle tissue, and joint cartilage.
On July 21, 2020, the FDA approved an 8% capsaicin patch to treat adults with neuropathic pain caused by diabetic peripheral neuropathy of the feet. The patch is a topical, non-systemic, non-opioid pain treatment that is the first and only treatment of its kind to deliver prescription-strength capsaicin directly into the skin.
Topical Analgesics Market Geographical Analysis
The North American region is expected to hold the largest market share globally topical analgesics market.
The well-established healthcare facilities, increasing geriatric population, and increased chronic pain prevalence in this region are expected to fuel the global topical analgesics market.
For instance, According to the CDC, an estimated 78.4 million (25.9 percent of the projected total adult population) adults aged 18 and older in the United States will have doctor-diagnosed arthritis by 2040. The increasing FDA approvals are also expected to boost the market growth. For instance, on February 14, 2020, the U.S FDA approved three drugs for non-prescription or over-the-counter (OTC) use via a process known as a prescription (Rx)-to-OTC switch. Among which is the Voltaren Arthritis Pain (diclofenac sodium topical gel, 1 percent) for the temporary relief of arthritis pain.
Topical Analgesics Market Competitive Landscape
The global topical analgesics market is highly competitive with increasing FDA approvals, company mergers, and topical pain relief medication demand. Some of the primary critical players in the market are AdvaCare Pharma, GlaxoSmithKline plc., Johnson & Johnson, Pfizer Inc., Hisamitsu Pharmaceutical co., inc., Sanofi, Sun Pharmaceutical Industries Ltd, Topical BioMedics, Inc., Teva Pharmaceutical Industries Ltd, Bayer AG.
GlaxoSmithKline plc
Overview: GlaxoSmithKline (GSK) is a pharmaceutical company that discovers, develops, manufactures, and markets human health products. The company was founded in 2000. It has its headquarters in Brentford, United Kingdom.
Product Portfolio: The company's product portfolio of (systemic and topical) pain relief products include Advil, Panadol, and Voltaren world's best-known brands. And their famous local brands such as Excedrin in the United States and Fenbid in China.
Critical Development: On February 17, 2020, GlaxoSmithKline FDA approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1 percent (NSAID)- arthritis pain reliever) as an over the counter (OTC) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle, or knee in adults (18 years and older). Voltaren Arthritis Pain is the first and only prescription-strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the United States, thanks to the FDA's approval.
